EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study

On Thursday, Nexalin Technology, Inc (NASDAQ:NXL) (NASDAQ:NXLIW) announced results from a clinical trial of its Deep Intracranial Frequency Stimulation (DIFS) technology for mild Alzheimer’s disease.

The full results have been published in Alzheimer’s Research & Therapy.

The study demonstrated improvements in memory and cognitive function for patients with mild Alzheimer’s disease using DIFS technology.

Also Read: Nano-Cap Nexalin Technology Secures US Patent For Stimulation Device For Alzheimer’s And Dementia Treatment.

The 46-patient study showed that those in the DIFS group (23 patients) saw notable improvements in key cognitive markers, including significant gains in Mini-Mental State Examination (MMSE) scores (p = 0.041) and Montreal Cognitive Assessment (MoCA) scores (p = 0.025).

Compared to the sham group, the DIFS group exhibited a statistically significant improvement in memory, as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog).

The intervention also increased local neural activity in the hippocampus, a crucial brain area for memory processing.

Nexalin’s DIFS treatment also showed increased blood flow to the hippocampal regions critical to memory function. The treatment was well-tolerated, with minor side effects such as mild tingling during stimulation sessions, resolved quickly.

Mark White, CEO of Nexalin Technology, further noted, “Our DIFS technology shows great promise as a drug-free alternative or in combination with existing treatments by working directly on the brain’s electrical activity to modulate cognition. The increase in both neural activity and blood flow in critical areas like the hippocampus indicates that this therapy could potentially slow disease progression.”

Price Action: At last check Thursday, NXL stock was up 4.76% at $1.10 during the premarket session.

Also Read:

• Syfovre’s Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch.